Was Douglas Carr’s Century Therapeutics (IPSC) share sale a discretionary trade?

No, the Form 4 specifies the sale was automatic and not at his discretion. The shares were sold solely to satisfy tax withholding obligations triggered by the vesting of restricted stock units, rather than a voluntary open-market sale decision.

Century Therapeutics SVP logs small automatic share sale

Century Therapeutics SVP Finance & Operations Douglas Carr reported a small automatic sale of 249 shares of common stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Century Therapeutics SVP Finance & Operations Douglas Carr reported a small automatic sale of 249 shares of common stock. The shares were sold on June 8, 2026 at $2.111 per share to cover tax withholding obligations tied to vesting restricted stock units. According to the filing, these sales were automatic and not at Carr’s discretion. After the transaction, he directly holds 506,748 shares of Century Therapeutics common stock.

Insider Trade Summary

Net Seller: 249 shares

Net Sell 1 txn

Insider Carr Douglas

Role SVP Finance & Operations

Sold 249 shs ($525.64)

Type	Security	Shares	Price	Value
Sale	Common Stock	249	$2.111	$525.64

Holdings After Transaction: Common Stock — 506,748 shares (Direct)

Footnotes (1)

F1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Key Figures

Shares sold: 249 shares Sale price: $2.111 per share Post-transaction holdings: 506,748 shares

3 metrics

Shares sold 249 shares Open-market sale on June 8, 2026

Sale price $2.111 per share Price for Century Therapeutics common stock in reported sale

Post-transaction holdings 506,748 shares Direct ownership after the June 8, 2026 transaction

Key Terms

restricted stock units, tax withholding obligations, automatic

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"required to be sold ... to cover tax withholding obligations"

automatic financial

"Such sales were automatic and not at the discretion of the Reporting Person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Century Therapeutics (IPSC) executive Douglas Carr report in this Form 4?

Douglas Carr reported an automatic sale of 249 Century Therapeutics shares. The shares were sold to cover tax withholding obligations related to vesting restricted stock units, and the filing notes the sale was not made at his discretion.

How many Century Therapeutics (IPSC) shares did Douglas Carr sell and at what price?

Douglas Carr sold 249 shares of Century Therapeutics common stock at $2.111 per share. The transaction occurred on June 8, 2026 and was executed solely to satisfy tax withholding obligations from restricted stock unit vesting.

Why were Douglas Carr’s Century Therapeutics (IPSC) shares sold in this transaction?

The shares were sold to cover tax withholding obligations from RSU vesting. The filing states that the number of shares sold represented the amount required for taxes and that these sales were automatic, not discretionary trades by Carr.

How many Century Therapeutics (IPSC) shares does Douglas Carr own after the reported sale?

After the transaction, Douglas Carr directly holds 506,748 Century Therapeutics shares. This indicates that the 249 shares sold for tax withholding represent only a small portion of his overall direct ownership position in the company’s common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/09/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carr Douglas

(Last)

(First)

(Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 12TH FLOOR

(Street)

PHILADELPHIA

PENNSYLVANIA

19104

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP Finance & Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/08/2026		S⁽¹⁾		249	D	$2.111	506,748	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

	/s/ Douglas Carr	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR